ABBV-CLS-484 History and Updates

4 events · 2021 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 18, 2026.

FDA Approvals

Label Revisions

Trial Milestones

Pivotal Publications

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-08Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for ABBV-CLS-484 since 2021, drawn from openFDA, ClinicalTrials.gov, and PubMed.

Upcoming & expected milestones

Primary completionOct 31, 2026· ClinicalTrials.gov

Phase 1 primary completion: NCT04777994

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Past events

2024

Trial registeredJan 3, 2024· ClinicalTrials.gov

Trial registered on ClinicalTrials.gov: NCT06188975

Expanded Access to ABBV-CLS-484

2021

Trial startedMar 9, 2021· ClinicalTrials.gov

Phase 1 trial started: NCT04777994

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Trial registeredMar 2, 2021· ClinicalTrials.gov

Phase 1 trial registered on ClinicalTrials.gov: NCT04777994

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.